Furmonertinib+cisplating/pemetrexed

Phase 2Small molecule

Furmonertinib+cisplating/pemetrexed is one of 37 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Nano-Crystalline Megestrol Acetate

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 3

1 2

Anktiva

SSWOG Cancer Research Network

Phase 3

1 3

Carboplatin/paclitaxel

AstraZeneca

Phase 3

3 4

Remeron

OOrganon and Co

Preclinical

1 5

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—6

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 8

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 9

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—10

Furmonertinib+cisplating/pemetrexed

TTang-Du Hospital

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 2Active, not recruiting

Non-Small Cell Lung Cancer

NCT05430802

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Furmonertinib Combined With Cisplatin/Pemetrexed as Neoadjuvant Therapy in EGFR Mutated Stage IIA-IIIB Resectable Non-small Cell Lung Cancer (FORESEE): a Prospective, Open-label, Single-arm, Phase 2 Study

Active, not recruiting·TTang-Du Hospital·Phase 2·NCT05430802·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Furmonertinib+cisplating/pemetrexed. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Furmonertinib+cisplating/pemetrexed compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Furmonertinib+cisplating/pemetrexed. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tang-Du Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTang-Du Hospital

Furmonertinib+cisplating/pemetrexed

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News